DHX30

DHX30 is a DExH-box ATP-dependent RNA helicase that governs translational output across both the cytoplasmic and mitochondrial compartments and functions as an antiviral effector (PMID:34020708, PMID:34503222). In the cytoplasm, DHX30 acts with PCBP2 to bind a 3' UTR CG-rich motif (CGPD-motif) on p53-dependent apoptotic mRNAs and represses their translation, such that DHX30 depletion derepresses these transcripts and shifts cells toward apoptosis (PMID:32234473); more broadly, the cytoplasmic isoform restrains global translation, and its loss enhances ribosomal protein mRNA translation while reducing translation of nuclear-encoded mitoribosome transcripts that it binds directly (PMID:34503222). A distinct, more abundant mitochondrial isoform localizes to mitochondrial RNA granules where it is required for mitoribosome assembly, mitochondrial translation, and OXPHOS complex formation (PMID:36163369). DHX30 additionally serves as an intrinsic antiviral factor: it is required for optimal ZAP-mediated viral mRNA elimination through an N-terminal interaction with ZAP (PMID:21204022), restricts HIV-1 RNA packaging (PMID:18022663), and inhibits Seneca Valley virus replication via helicase-dependent viral RNA binding and interaction with the viral 3D polymerase, an activity the viral 3Cpro protease cleaves to antagonize (PMID:36000840). De novo missense mutations in conserved helicase core motifs abolish ATPase and helicase activity and confer a toxic gain-of-function that triggers stress granule assembly and global translation inhibition, causing a severe neurodevelopmental disorder, whereas loss-of-function variants produce a milder phenotype (PMID:29100085, PMID:34020708).

1. 2007 Medium

   Established the first functional role for DHX30, showing it inhibits HIV-1 RNA packaging despite enhancing viral gene expression, the earliest evidence linking the protein to RNA-virus biology.

   Evidence Overexpression in cell culture with viral RNA quantification and infectivity assays

   PMID:18022663

   Open questions at the time

   • Mechanism by which DHX30 restricts packaging unresolved
   • No demonstration of direct viral RNA binding in this study
   • Reliance on overexpression rather than endogenous loss
2. 2010 Medium

   Defined DHX30 as a cofactor of the zinc-finger antiviral protein ZAP, showing it is required for optimal ZAP-mediated elimination of viral mRNAs and extending its antiviral role to a defined protein partner.

   Evidence Pull-down and reciprocal co-immunoprecipitation mapping an N-terminal interaction, plus shRNA knockdown with antiviral readout

   PMID:21204022

   Open questions at the time

   • Whether DHX30 helicase activity is needed for ZAP function not tested
   • Single lab
   • Structural basis of the N-terminal interaction unknown
3. 2014 Medium

   Demonstrated catalytic helicase (unwinding) activity of purified DHX30 and its non-redundant requirement in early mammalian development.

   Evidence In vitro helicase/untwisting assay with purified protein and gene-trap homozygous mouse model

   PMID:25219788

   Open questions at the time

   • Physiological RNA substrate not defined
   • Developmental lethality not mapped to a molecular function
   • DNA-unwinding readout leaves RNA preference open
4. 2017 High

   Linked DHX30 to human disease, showing de novo missense mutations in helicase motifs impair ATPase or RNA recognition and promote stress granule formation with translation inhibition.

   Evidence In vitro ATPase and RNA-binding assays, stress granule and global translation assays on patient-derived variants

   PMID:29100085

   Open questions at the time

   • Endogenous RNA targets in neurons not identified
   • SG composition and persistence not fully characterized
   • Genotype-phenotype correlation not yet established
5. 2020 Medium

   Identified a sequence-specific translational repression mechanism, showing DHX30 with PCBP2 binds 3' UTR CGPD-motif mRNAs to repress p53-dependent apoptotic transcripts and tune the apoptosis-versus-arrest decision.

   Evidence Polysome profiling, RNA immunoprecipitation, shRNA knockdown and inducible overexpression with apoptosis/translation readouts

   PMID:32234473

   Open questions at the time

   • Whether ATPase/helicase activity is required for repression not resolved
   • Direct vs PCBP2-bridged RNA contact not separated
   • In vivo relevance untested
6. 2021 Medium

   Distinguished cytoplasmic and mitochondrial isoforms and established the cytoplasmic isoform as a modulator of global translation that directly binds nuclear-encoded mitoribosome transcripts.

   Evidence Isoform-specific siRNA knockdown, polysome profiling, RIP, eCLIP, and mitochondrial metabolic and proliferation assays in multiple cell lines

   PMID:34503222

   Open questions at the time

   • Direct mechanism coupling translation control to proliferation not defined
   • Single lab
   • How the two isoforms are differentially generated/targeted unclear
7. 2021 High

   Resolved the disease mechanism, showing gain-of-function SG-triggering missense variants cause severe disease while loss-of-function variants cause a milder phenotype, and confirmed DHX30 as a conserved SG factor in vivo.

   Evidence ATPase, helicase, SG and translation assays plus CRISPR DHX30-deficient HEK293T and zebrafish models with behavioral phenotyping

   PMID:34020708

   Open questions at the time

   • Neuronal RNA targets driving pathology not defined
   • How SG assembly translates to developmental defects unknown
   • Therapeutic correction not addressed
8. 2022 Medium

   Placed DHX30 in mitochondrial RNA granules as a requirement for mitoribosome assembly and translation, and showed ALS-mutant FUS mislocalizes DHX30 to stress-granule aggregates via aberrant disulfide-induced conformational change.

   Evidence Co-IP, subcellular fractionation, density-gradient and detergent-solubility analysis, blue-native PAGE, immunofluorescence, immunoelectron microscopy and DHX30 knockdown

   PMID:36163369

   Open questions at the time

   • Identity of mitochondrial RNA substrates within granules not defined
   • Direct vs indirect role in mitoribosome assembly unresolved
   • Generality beyond mutant FUS context unknown
9. 2022 Medium

   Showed DHX30 is an intrinsic antiviral RNA-binding factor against Seneca Valley virus acting through its helicase activity, and that the viral 3Cpro protease cleaves it to disable restriction.

   Evidence LC-MS/MS, co-IP, RIP-seq, overexpression/knockdown viral replication assays, dsRNA quantification and protease cleavage assay

   PMID:36000840

   Open questions at the time

   • Whether antiviral function requires ZAP partnership not tested
   • Mechanism of dsRNA suppression not detailed
   • Single virus system
10. 2024 Low

    Implicated DHX30 in neuronal mRNA stabilization, acting as a partner recruited by lncRNA Anxa10-203 to stabilize Mc1r mRNA and increase neuronal excitability.

    Evidence RNA pull-down, RNA immunoprecipitation, immunofluorescence, RNA-FISH and electrophysiology in trigeminal ganglion neurons

    PMID:38433184

    Open questions at the time

    • RNA pull-down and RIP without reconstitution or mutagenesis to confirm direct interaction
    • Helicase-activity dependence not tested
    • Single lab, single physiological context

• How DHX30's distinct activities — sequence-specific translational repression, mitoribosome assembly, antiviral RNA surveillance and pathogenic SG nucleation — are coordinated by a shared catalytic mechanism and which endogenous RNA substrates drive each remains unresolved.
• No unifying structural model of substrate engagement
• Comprehensive endogenous RNA target map across compartments lacking
• Link between molecular activity and the neurodevelopmental phenotype not mechanistically closed